Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1/2 1Phase 1 1

Status

Recruiting 2Active not recruiting 2Completed 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 5

Conditions

Pancreatic Neoplasms 115Urinary Bladder Neoplasms 56Carcinoma, Non-Small-Cell Lung 53Cholangiocarcinoma 33Biliary Tract Neoplasms 32Neoplasm Metastasis 30Ovarian Neoplasms 29Lymphoma, Large B-Cell, Diffuse 27Breast Neoplasms 25Neoplasms 24Lung Neoplasms 24Carcinoma, Transitional Cell 23Triple Negative Breast Neoplasms 22Nasopharyngeal Carcinoma 21Colorectal Neoplasms 20Non-Muscle Invasive Bladder Neoplasms 19Recurrence 17Fallopian Tube Neoplasms 16Gallbladder Neoplasms 15Sarcoma 13Bile Duct Neoplasms 11Parkinson Disease 4, Autosomal Dominant Lewy Body 10Hodgkin Disease 10Lymphoma 9Adenocarcinoma 9Uterine Cervical Neoplasms 8Stomach Neoplasms 7Lymphoma, Non-Hodgkin 7Endometrial Neoplasms 7Nasopharyngeal Neoplasms 6

Interventions

Gemcitabine 5Taxes 3Albumin-Bound Paclitaxel 3Radiotherapy, Intensity-Modulated 2Radiotherapy 2Oxaliplatin 2Losartan 2Leucovorin 2Irinotecan 2Fluorouracil 2130-nm albumin-bound paclitaxel 2tocilizumab 1selicrelumab 1niraparib 1durvalumab 1dehydroftorafur 1cobimetinib 1atezolizumab 1X-Rays 1Tiragolumab 1Standard of Care 1Specimen Handling 1Radiation 1Panitumumab 1Pancreaticoduodenectomy 1PEGPH20 1Optical Imaging 1Nivolumab 1Metformin 1Ipilimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Pancreatic Adenocarcinoma × Gemcitabine × 1 year × Clear all
NCT05624918 2026-04-08

A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma

Big Ten Cancer Research Consortium

Phase 2 Recruiting
38 enrolled
Gastrointestinal

Pancreatic Adenocarcinoma

NCT02336087 2026-02-04

Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Pancreatic Cancer That Cannot be Removed by Surgery

City of Hope Medical Center

Phase 1 Active not recruiting
21 enrolled
Gastrointestinal

Pancreatic Adenocarcinoma

NCT04539808 2026-01-14

NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer

OHSU Knight Cancer Institute

Phase 2 Active not recruiting
42 enrolled 13 charts
Gastrointestinal

Pancreatic Adenocarcinoma

NCT03193190 2025-11-21

A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

Hoffmann-La Roche

Phase 1/2 Completed
341 enrolled 28 charts
Gastrointestinal

Pancreatic Adenocarcinoma

NCT06250972 2025-08-07

PTCA199-11

Fudan University

Phase 3 Recruiting
210 enrolled
Gastrointestinal

Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡